Start the conversation
The stock is up 73% since Monday and 107% since we recommended it to you back in early February. It ended yesterday higher by 24.6%.
The surge this week is due to several announcements the company has made. On Tuesday, we told you that the Blue Bell, Pa.-based biotech said that its universal H7N9 "Bird Flu" DNA Vaccine protected 100% of vaccinated animals in a challenge study.
This company - headed by CEO J. Joseph Kim - has an exceptional management team, promising technology and an extremely promising outlook, says Michael Robinson, our resident tech expert and the editor of the Radical Technology Profits advisory service.
This is premium content for Private Briefing subscribers only.